Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma

Annals of Surgical Oncology

Volumn 16, Issue 10, 2009, Pages 2926-2935

  Yashiro, Masakazu ^a   Inoue, Toru ^a   Nishioka, Nobuaki ^a   Matsuoka, Tasuku ^a   Boland, C Richard ^b   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; K RAS PROTEIN; PROTEIN P53; ANTINEOPLASTIC AGENT; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; LOW DRUG DOSE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PREDICTOR VARIABLE; STOMACH CARCINOMA; TUMOR BIOPSY; ADJUVANT THERAPY; CANCER STAGING; DRUG RESISTANCE; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; ONCOGENE RAS; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; STOMACH TUMOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ALLELIC IMBALANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73349127495     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0590-6     Document Type: Article

References (36)

1. D'Ugo D, Persiani R, Rausei S, Biondi A, Vigorita V, Boccia S, et al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol. 2006;32:1105-9.
2. Ng K, Meyerhardt JA, Fuchs CS. Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J. 2007;13:168-74.
3. Lutz MP, Wilke H, Wagener DJ, Vanhoefer U, Jeziorski K, Hegewisch-Becker S, et al. Weekly infusional high-dose fluoro-uracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: ran-domized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2007;25:2580-5.
4. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, et al. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer. 1997;80:1-7.
5. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
6. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, et al. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol. 2006;17:1404-11.
7. De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, et al. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol. 2007;18 Suppl 6:vi120-3.
8. Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest. 2006;24:235-41.
9. Hofler H, Langer R, Ott K, Keller G. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastroin-testinal tract. Recent Results Cancer Res. 2007;176:33-6
10. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-67.
11. Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol. 2006;4:416-25.
12. Rhyu MG, Park WS, Jung YJ, Choi SW, Meltzer SJ. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology. 1994;106:1584-8.
13. Houghton JA, Ebanks R, Harwood FG, Tillman DM. Inhibition of apoptosis after thymineless stress is conferred by oncogenic K-Ras in colon carcinoma cells. Clin Cancer Res. 1998;4:2841-8.
14. Jascur T, Boland CR. Structure and function of the components of the human DNA mismatch repair system. Int J Cancer. 2006;119:2030-5.
15. Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 2003;63:1608-14.
16. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Nied-zwiecki D, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132:127-38.
17. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro responseto5-fluorouracil. Gastroenterology. 1999;117:123-31.
18. Zoli W, Ricotti L, Lenzi L, Roncuzzi L, Zini N, Amadori D, et al. Molecular genetics and in vitro sensitivity of a new human cell line, KKP, from a gastric adenocarcinoma. Cancer Genet Cyto-genet. 1998;105:43-9.
19. Ott K, Vogelsang H, Mueller J, Becker K, Müller M, Fink U, et al. Chromosomal instability rather than p53 mutation is asso-ciated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res. 2003;9:2307-15.
20. Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, et al. Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carci-noma. Clin Cancer Res. 2000;6:4782-88
21. Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma-2nd English Edition. Gastric Cancer. 1998;1:10-24.
22. Kim MA, Lee HS, Yang HK, Kim WH. Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer 2005;103:1439-46.
23. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
24. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial pre-disposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-57.
25. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res. 2001;61:2676-83.
26. Inada T, Ogata Y, Kubota T, Tomikawa M, Yamamoto S, Andoh J, et al. 5-fluorouracil sensitivity and dihydropyrimidine dehy-drogenase activity in advanced gastric cancer. Anticancer Res. 2000;20:2457-62.
27. Ozguroglu M, Demir G. Expression ofp53 protein and resistance to preoperative chemotherapy in locally advanced gastric carci-noma. Cancer. 1999;86:547-9.
28. Cascinu S, Graziano F, Del Ferro E, Staccioli MP, Ligi M, Carnevali A, et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carci-noma. Cancer. 1998;83:1917-22.
29. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, et al. p53 alterations predict tumor response to neo-adjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol. 2000;18:1465-73.
30. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymor-phism among Caucasian and Asian populations. Genomics. 1999;58:310-2.
31. Ming SC Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review. Gastric Cancer. 1998;1:31-50.
32. Parker WB, Cheng YC Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381-95.
33. Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, et al. A comparative study ofp53 gene mutations, protein accumulation, and response to cisplatin-based chemo-therapy in advanced ovarian carcinoma. Cancer Res. 1996;56:689-93.
34. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-67.
35. Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol. 1990;68:1071-4.
36. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996;56:3087-90.